The Effective Use of Insulin in Type 2 Diabetes: A Focus on Treatment Advances - Webcast

The webcast activity The Effective Use of Insulin in Type 2 Diabetes: A Focus on Treatment Advances was originally presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, on April 1, 2016.

This activity is supported by an educational grant from sanofi-aventis U.S. Inc.

 

Target Audience

This activity is intended for endocrinologists, internists, surgeons, basic scientists, and other health care professionals with a shared special interest in the latest advances in hormone research and clinical endocrinology.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Recognize the scope of the disease burden of hypoparathyroidism and its complications
  • Weigh the advantages, limitations, and safety of available treatment options
  • Summarize the evidence and principles of recently published guidelines

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 ABIM MOC
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
04/15/2016
Course expires: 
04/18/2017
Rating: 
0
Boston, MA 02210
United States

Jack Leahy, MD - Program Director
Professor of Medicine
Chief of Endocrinology, Diabetes, and Metabolism
Unviersity of Vermont
Colchester, Vermont

Lawrence Blonde, MD
Driector, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

Marie McDonnell, MD
Director, Brigham Diabetes Program
Endocrinology, Diabetes, and Hypertension
Boston, Massachusetts

Janet McGill, MD
Director, Fellowship in Endocrinology, Diabetes, and Metabolism
Division of Endocrinology, Metabolism and Lipid Research
Washington University School of Medicine
St. Louis, Missouri

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Larry Blonde, MD: Consultant, Merck & Co., GlaxoSmithKline, Intarcia; Investigator, Novo Nordisk, Sanofi; Speaker, AstraZeneca, Jansen Pharmaceuticals; Principal Investigator, Eli Lilly & Co.
Jack Leahy, MD: Advisory Board Member, Janssen, Merck, Novo Nordisk, Roche, Sanofi
Janet McGill, MD: Advisory Board Member, Eli Lilly, Janssen Pharmaceuticals, Merck & Co., Novo Nordisk; Consultant, Boehringer Ingelheim; Principal Investigator, Dexcom, Lexicon Pharmaceuticals, Inc., Novartis Pharmaceuticals, Pfizer Global R&D; Speaker, Janssen Pharmaceuticals

The following faculty reported no relevant financial relationship(s): Marie McDonnell, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and ASiM staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 ABIM MOC
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
04/15/2016
Course expires: 
04/18/2017